Hetero, one of India’s leading generic pharmaceutical companies, announced today that it has received the manufacturing and marketing approval for the investigational antiviral medicine ‘Remdesivir’ from the Drug Controller General of India (DCGI) for the treatment of Covid-19. Hetero’s generic version of Remdesivir will be marketed under the brand name ‘COVIFOR’ in India.
source https://www.pharmatutor.org/pharma-news/2020/hetero-receives-dcgi-nod-for-remdesivir
No comments:
Post a Comment